SYNB:NYE-Putnam Biorevolution ETF (USD)

ETF | Others |

Last Closing

USD 28.881

Change

-0.52 (-1.77)%

Market Cap

USD 5.39M

Volume

2.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SOJE Southern Company (The) Series ..

-0.09 (-0.48%)

USD 65.72B
JEPI JPMorgan Equity Premium Income..

-0.72 (-1.23%)

USD 40.21B
SGOV iShares® 0-3 Month Treasury B..

+0.01 (+0.01%)

USD 35.73B
DFAC Dimensional U.S. Core Equity 2..

-0.45 (-1.31%)

USD 33.57B
JPST JPMorgan Ultra-Short Income ET..

N/A

USD 30.68B
DTB DTE Energy Company 2020 Series

-0.12 (-0.62%)

USD 26.58B
JAAA Janus Detroit Street Trust - J..

-0.03 (-0.06%)

USD 21.88B
GBTC Grayscale Bitcoin Trust (BTC)

+0.71 (+1.04%)

USD 19.50B
AVUV Avantis® U.S. Small Cap Value..

-1.87 (-2.07%)

USD 15.35B
CGDV Capital Group Dividend Value E..

-0.58 (-1.58%)

USD 13.61B

ETFs Containing SYNB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.34% 23% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.34% 22% F 30% F
Trailing 12 Months  
Capital Gain -5.13% 13% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.13% 9% A- 21% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.40% 72% C 55% F
Dividend Return 6.40% 67% D+ 48% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.78% 62% D 84% B
Risk Adjusted Return 82.20% 83% B 87% B+
Market Capitalization 5.39M 10% F 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.